Guardant Health Stock Price, News & Analysis

Guardant Health (Nasdaq: GH) expanded its tissue-free Guardant Reveal blood test on November 10, 2025 to include late-stage therapy response monitoring for patients with solid tumors.

Reveal analyzes >20,000 epigenomic methylation signals in circulating tumor DNA to predict therapy response across immunotherapy and chemotherapy, can be initiated anytime during treatment, and returns actionable insights in seven days. Clinical validation cited includes a pan-cancer chemotherapy study showing prediction of long-term benefit up to 18 months earlier and the RADIOHEAD study showing immunotherapy responses detected up to 5 months earlier than standard imaging. A new universal one-click ordering option was also launched to streamline physician ordering across Guardant’s portfolio.

Guardant Health (Nasdaq: GH) will participate in two investor conferences in late 2025: a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 9:30 a.m. GMT, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on Tuesday, December 2, 2025 at 8:30 a.m. ET. Interested parties may access live and archived webcasts via the company’s Investors website at www.guardanthealth.com.

Guardant Health (Nasdaq: GH) announced that its Compensation Committee approved inducement equity grants for new non‑executive hires under the 2023 Employment Inducement Incentive Award Plan. On October 21, 2025 the committee approved RSUs representing 184,961 shares to 272 new non‑executive employees and one non‑qualified stock option to purchase 5,731 shares, with a grant date of October 31, 2025.

The RSUs vest one‑third annually on each anniversary of the vesting commencement date, subject to continued employment. The stock option exercise price is $93.02 per share (closing price on October 31, 2025); one‑third vests after one year, then monthly over 24 months thereafter, subject to continued employment.

Guardant Health (Nasdaq: GH) announced a clinical validation showing the Guardant Reveal blood test can monitor chemotherapy response in advanced solid tumors earlier than conventional methods.

The study found any post‑treatment decrease in a methylation‑based circulating tumor DNA (ctDNA) tumor fraction signal correlated with longer treatment duration and higher survival; a >98% reduction produced the largest benefit. A rise in the tumor signal identified disease progression up to 18 months earlier with a median lead time of 2.3 months. Guardant Reveal analyzes nearly 30,000 methylated regions and is tissue‑free, enabling broader pan‑cancer monitoring over time.

Guardant Health (Nasdaq: GH) reported real‑world data showing the Shield blood-based colorectal cancer screening test had 95% adherence in the first 20,000 patients with clinical orders from May 2022–June 2024. Shield is the first blood test with FDA approval as a primary screening option for average‑risk adults aged 45+. Median turnaround time was 15 days from sample receipt to report.

An additional Appalachian clinic analysis showed screening rates rose from 45% to 90% after Shield was offered and a 98.5% adherence rate. Shield is covered by Medicare and the VA Community Care Network and is commercially available across the U.S.

Guardant Health (Nasdaq: GH) priced an upsized underwritten public offering of 3,333,333 shares of common stock at $90.00 per share, up from a previously announced $250.0 million size. The company granted underwriters an option for an additional 499,999 shares. The offering is expected to close on November 7, 2025, subject to customary closing conditions.

Guardant estimates net proceeds of approximately $284.4 million (excluding any option exercise). Concurrently, Guardant priced an upsized convertible notes offering of $350.0 million principal amount due 2033, with an option for an additional $52.5 million. Proceeds are planned for general corporate purposes and may include repurchasing a portion of its 0% convertible senior notes due 2027, though no repurchase agreement is in place.

Guardant Health (Nasdaq: GH) priced an upsized private offering of $350.0 million aggregate principal amount of 0% convertible senior notes due May 15, 2033, with settlement expected on November 7, 2025. The initial purchasers have a 13-day option to buy an additional $52.5 million of notes. The notes bear no regular interest, are senior unsecured, and convert at an initial rate of 8.2305 shares per $1,000 principal (initial conversion price ~$121.50), a ~35% premium to the concurrent public offering price.

Guardant also priced a concurrent underwritten public offering of 3,333,333 shares at $90.00 per share (gross proceeds ~$300.0 million), with a 30-day option to buy up to 499,999 additional shares. Estimated net proceeds from the notes are ~$339.1 million (or ~$390.0 million if the option is exercised). Proceeds are intended for general corporate purposes, which may include repurchasing certain 2027 notes.

Guardant Health (Nasdaq: GH) announced a proposed underwritten public offering of $250.0 million of common stock and a 30‑day option for underwriters to buy up to an additional $37.5 million of shares. Guardant Health also announced a concurrent proposed offering of $300.0 million aggregate principal amount of convertible senior notes due 2033, with an initial purchaser option to buy up to an additional $45.0 million of notes.

Both offerings are subject to market and other conditions, are not contingent on each other, and will be made by prospectus supplement under a shelf registration. Net proceeds are intended for general corporate purposes and may include repurchasing a portion of the company’s 0% convertible senior notes due 2027, although no repurchase is assured.

Guardant Health (Nasdaq: GH) announced a proposed private offering of $300.0 million aggregate principal amount of convertible senior notes due May 15, 2033, with an initial purchaser option to buy up to an additional $45.0 million. The notes will be senior, unsecured, accrue interest semi‑annually, and will not be redeemable at GH’s election before November 20, 2029. Conversion may be settled in cash, shares or a combination at GH’s election.

Concurrently, GH intends to offer $250.0 million of common stock, with a 30‑day underwriter option for $37.5 million. Net proceeds are intended for general corporate purposes, which may include repurchasing a portion of GH’s 0% convertible senior notes due 2027, subject to market conditions and no assurances of completion.